NCT00318266View on ClinicalTrials.gov

NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers.

CompletedOBSERVATIONAL
Enrollment

73

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Bladder Cancer
Interventions
DEVICE

Nuclear Matrix Protein 22 Urine sample kit

Urine sample obtained from patient will be tested with the NMP22 sample kit to see if it can detect bladder cancer.

Trial Locations (1)

N6A 4G5

London Health Sciences Centre, London

All Listed Sponsors
lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

NCT00318266 - NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers. | Biotech Hunter | Biotech Hunter